Sold as Penbritin-S, Polycillin-N. Every FDA application for this active ingredient: 2 branded and 30 generic.
As of Nov 16, 2026, FDA lists 32 applications for Ampicillin Sodium (sold as Penbritin-S, Polycillin-N), first approved Dec 29, 1966, with 0 new uses approved and 0 published complete response letters.
| Ampicillin Sodium | Part D | $4.8M | +4% | 4,140 |
| Ampicillin Sodium | Part B | $5K | -53% | 442 |
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Ampicillin Sodium Injection | To Be Discontinued | Dec 8, 2025 | Dec 8, 2025 |
| Dec 29, 1966 | Penbritin-SNDA 50072 | Wyeth Ayerst | 1 | Discontinued |
| Mar 3, 1971 | Ampicillin SodiumANDA 61395 | Sandoz | 11 | Marketed |
| Jun 24, 1986 | Ampicillin SodiumANDA 62692 | Hikma | 2 | Discontinued |
| Dec 19, 1986 | Totacillin-NANDA 62727 | Glaxosmithkline | 1 | Discontinued |
| Feb 19, 1987 | Ampicillin SodiumANDA 62738 | Sandoz | 9 | Discontinued |
| May 12, 1987 | Ampicillin SodiumANDA 62719 | Acs Dobfar Spa | 9 | Marketed |
| Sep 15, 1988 | Ampicillin SodiumANDA 62994 | Chartwell Rx | 15 | Discontinued |
| Oct 28, 1988 | Ampicillin SodiumANDA 62816 | Chartwell Rx | 17 | Discontinued |
| Apr 15, 1993 | Ampicillin SodiumANDA 62772 | Hq Speclt Pharma | 7 | Marketed |
| Apr 15, 1993 | Ampicillin SodiumANDA 63142 | Hq Speclt Pharma | 9 | Marketed |
| Apr 15, 1993 | Ampicillin SodiumANDA 63147 | Hanford Gc | 5 | Discontinued |
| Jul 12, 1993 | Ampicillin SodiumANDA 62797 | Acs Dobfar Spa | 5 | Marketed |
| Dec 28, 2009 | Ampicillin SodiumANDA 90354 | Antibiotice | 3 | Marketed |
| Aug 17, 2010 | Ampicillin SodiumANDA 65493 | Eugia Pharma Speclts | 3 | Marketed |
| Aug 17, 2010 | Ampicillin SodiumANDA 65499 | Eugia Pharma Speclts | 4 | Marketed |
| Apr 3, 2013 | Ampicillin SodiumANDA 90884 | Acs Dobfar Spa | 3 | Discontinued |
| Apr 3, 2013 | Ampicillin SodiumANDA 90889 | Acs Dobfar Spa | 3 | Marketed |
| Dec 20, 2013 | Ampicillin SodiumANDA 201404 | Acs Dobfar Spa | 3 | Marketed |
| Apr 7, 2014 | Ampicillin SodiumANDA 202198 | Onesource Specialty | 4 | Marketed |
| Apr 9, 2014 | Ampicillin SodiumANDA 201025 | Onesource Specialty | 3 | Marketed |
| Sep 4, 2015 | Ampicillin SodiumANDA 202864 | Hospira | 1 | Discontinued |
| Sep 4, 2015 | Ampicillin SodiumANDA 202865 | Hospira | 1 | Discontinued |
| Oct 20, 2015 | Ampicillin SodiumANDA 90581 | Sagent Pharms Inc | 3 | Marketed |
| Nov 27, 2015 | Ampicillin SodiumANDA 90583 | Sagent Pharms Inc | 4 | Marketed |
| — | Polycillin-NNDA 50309 | Bristol | 0 | Discontinued |
| — | Omnipen-NANDA 60626 | Wyeth Ayerst | 0 | Discontinued |
| — | Totacillin-NANDA 60677 | Glaxosmithkline | 0 | Discontinued |
| — | Ampicillin SodiumANDA 61936 | Consolidated Pharm | 0 | Discontinued |
| — | Ampicillin SodiumANDA 62565 | Lilly | 0 | Discontinued |
| — | Ampicillin SodiumANDA 62634 | Intl Medication | 0 | Discontinued |
| — | Omnipen-NANDA 62718 | Wyeth Ayerst | 0 | Discontinued |
| — | Ampicillin SodiumANDA 62860 | Apothecon | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA